Investing
Bristol Myers wins dismissal of lawsuit over Celgene drugs
© Reuters. FILE PHOTO: A sign stands outside a Bristol Myers Squibb facility in Cambridge, Massachusetts, U.S., May 20, 2021. REUTERS/Brian Snyder
NEW YORK (Reuters) – A U.S. judge on Wednesday dismissed a lawsuit accusing Bristol Myers (NYSE:) Squibb Co of defrauding investors who stood to receive $6.4 billion had it won federal approval by specified deadlines for drugs developed by the former Celgene Corp (NASDAQ:).
Read the full article here
LA Rental Prices Skyrocketing Despite Price Gouging Laws
How to Craft Marketing Campaigns That Reach Multiple Generations
How Turning My Company Employee-Owned Saved Our Culture and Boosted Success
5 Risk-Taking Lessons From Founders Who Bet Big and Won
Exclusive-Investor climate group suspends activities after BlackRock exit By Reuters
Microsoft Is About to Begin Job Cuts. Here’s Why.
10 Critical Questions to Ask Your Financial Advisor Now
10 Ways to Make Money As a Graphic Designer
3 Challenges Entrepreneurs Will Face in 2025
What CMOs Need to Know About AI Adoption in Marketing Teams
Debt ceiling debate and its effect on the U.S. dollar
Debt ceiling default: Still no deal between parties
Stovall: If the U.S. defaults on its debt, all S&P 500 sectors will likely fall
What China's weaker-than-expected economy could mean for U.S. markets
A ‘Big Short’ investor sees financial disaster brewing in housing markets — again
-
Side Hustles6 days agoMicrosoft Is About to Begin Job Cuts. Here’s Why.
-
Make Money5 days ago10 Critical Questions to Ask Your Financial Advisor Now
-
Make Money4 days ago10 Ways to Make Money As a Graphic Designer
-
Passive Income7 days ago3 Challenges Entrepreneurs Will Face in 2025
-
Investing6 days agoWhat CMOs Need to Know About AI Adoption in Marketing Teams
-
Personal Finance3 days agoIf you are 60 years old, new 401(k) rules could save you money
-
Side Hustles7 days agoThe Canadian Media Lawsuit That Could Reshape Tech’s Future
-
Side Hustles6 days agoJPMorgan to Implement a Five-Day Return-to-Office Mandate